Advertisement

Irish Journal of Medical Science

, Volume 147, Issue 1, pp 308–312 | Cite as

Vibrio Cholerae neuraminidase susceptible n-acetyl neuraminic acid (sialic acid) levels in human leukaemia

  • Antoinette Hogan Ryan
  • J. J. Fennelly
Article

Summary

Cell surface vibrio Cholerae neuraminidase (VCN) susceptible sialic acid has been studied in leucocytes of normal human subjects and patients with acute myeloid, acute lymphatic and chronic lymphatic leukaemia as well as in myeloid metaplasia. The mean VCN susceptible sialic acid released in normal lymphocytes was 222±72 n mole/109 cells as compared to 158±n mole/109 cells in leukaemic lymphocytes, and 178±48 n mole/109 cells in leukaemic granulocytes. This release of surface sialic acid by VCN may play a part in increasing immunogenicity of leukaemic cells for immunotherapy.

Keywords

Sialic Acid Acute Myelogenous Leukaemia Normal Lymphocyte Leukaemic Cell Phate Buffer Saline 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aminoff, P. 1961. Methods for the quantitative estimation of N-acetylneuraminic acid and their application to hydrolysates of sialomucoids. Biochem. J. 81, 384.PubMedGoogle Scholar
  2. Bekesi, J. G., St. Arneault, G. and Holland, J. F. 1971. Increase in leukaemia L1210 immunogenicity by Vibrio Cholerae neuraminidase treatment. Cancer Res. 31, 2130.PubMedGoogle Scholar
  3. Bekesi, J. G., St. Arneault, G., Walter, L. and Holland, J. F. 1972. Immunogenicity of leukaemia L1210 cells after neuraminidase treatment. J. Natl. Cancer Inst. 49, 107.PubMedGoogle Scholar
  4. Gottschalk, A. and Bhargava, A. S. 1971. The Enzymes, Vol. V, 3rd Ed. New York, Academic Press, p. 321.Google Scholar
  5. Harris, R., Ukaeljiofo, E., Pierce, G. E. and Yang, J. P. 1969. Cellular and humoral immunity to different types of human neoplasms. Nature (Lond.) 220, 1352.Google Scholar
  6. Hogan Ryan, M. A. and Fennelly, J. J. 1978. Neuraminidase-like effect of vitamin A on cell surface. Eur. J. Cancer. 14, 113.PubMedGoogle Scholar
  7. Im, H. M. and Simmons, R. L. 1971. Modification of graft versus host disease by neuraminidase treatment of donor cells. Transplantation, 12, 472.PubMedCrossRefGoogle Scholar
  8. Kornfeld, S. 1969. Decreased phytohaemagglutinin receptor sites in chronic lymphocytic leukaemia. Biochem. Biophys. Acta, 192, 542.PubMedGoogle Scholar
  9. Lichtmann, M. A. and Weed, R. I. 1970. Electrophoretic mobility and N-acetylneuraminic acid content of normal and leukaemic lymphocytes and granulocytes. Blood, 35, 12.Google Scholar
  10. Lindenmann, J. and Klein, P. A. 1967. Immunological aspects of viral oncolysis: recent results. Cancer Res. 9, 1.Google Scholar
  11. Lundgren, G. and Simmons, R. L. 1971. Effect of neuraminidase on the stimulatory capacity of cells in mixed lymphocyte cultures. Clin Exptl. Immunol. 9, 915.Google Scholar
  12. Mehrishi, J. N. 1974. Cell surface membrane interactions with special reference to lymphocytes in leukaemia. Behring inst. Mitt No. 55, 290.Google Scholar
  13. Mehrishi, J. N. and Thompson, A. E. R. 1968. Relationship between pH and electrophoretic mobility for lymphocytes circulating in chronic lymphatic leukaemia. Nature (Lond), 219, 1080.CrossRefGoogle Scholar
  14. McClelland, D. A. and Bridges, J. M. 1973. The total N-Acetyl neuraminic acid content of normal and leukaemic lymphocytes. Br. J. Cancer. 27, 114.PubMedGoogle Scholar
  15. Powles, R. L., Crowther, D., Bateman, C. J. L., Beard, M. E. J., McElwain, T. J., Russell, J., Lister, T. A., Whitehouse, J. M., Wrigley, P. F. M., Pike, M., Alexander, P., Hamilton-Fairley, G. 1973. Immunotherapy for acute myelogenous leukaemia. Br. J. Cancer 28, 365.PubMedGoogle Scholar
  16. Rios, A. and Simmons, R. L. 1972. Comparative effect of Mycobacterium Bovis and neuraminidase treated tumour cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice. Cancer Research 32, 16.PubMedGoogle Scholar
  17. Rundell, J. O., Sato, T., Wetzelberger, E., Veda, H., Seiler, F. R., Sedlacek, H. H. 1974. Comparative studies on properties of lysosomes in L1210 leukaemia cells underin vivo andin vitro conditions. Lab. Invest. 30, 279.PubMedGoogle Scholar
  18. Seiler, F. R. and Sedlack, H. H. 1974. Alterations of immunological phenomena by neuraminidase. Behring, Inst. Mitt., No. 55, 254Google Scholar
  19. Sethi, K. K. and Brandis, H. 1973. Synergistic cytoxic effect of macrophages and normal mouse serum on neuraminidase-treated leukaemia cells. Europ. J. Cancer 9, 809Google Scholar
  20. Simmons, R. L., Rios, A. 1974. Immunospecific regression of methycholanthrene fibrosarcoma with the use of neuraminidase. Israel Med. Sci. 10, 925.Google Scholar
  21. Warren, L. 1959. The thiorbarbituric acid assay of sialic acids. J. Biol. Chem. 234, 1971.PubMedGoogle Scholar
  22. Weiss, L., Mayhew, E., Ulrich, K. 1966. The effects of neuraminidase on the phagocytic process in human monocytes. Lab. Invest. 15, 1304.PubMedGoogle Scholar
  23. Weiss, L. 1965. Studies on cell deformability. I. Effect of surface charge. J Cell Biol. 26, 735.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • Antoinette Hogan Ryan
    • 1
  • J. J. Fennelly
    • 1
  1. 1.Department of Medicine and TherapeuticsUniversity College and St. Vincent's HospitalDublin 4

Personalised recommendations